Can Antisense Trump Oral?
'In a Year, We'll Know': Isis' Kynamro Faces Juxtapid Pill
By Randy Osborne
Wednesday, January 30, 2013
Timing of the launch, how to identify new patients and the retry for approval in Europe along with, of course, price became topics of talk in the aftermath of Kynamro's approval Tuesday by the FDA for homozygous familial hypercholesterolemia (HoFH).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.